Source comparison
MK-677 for Women: Research Protocol Comparison
Understanding how different MK-677 protocols produce varying outcomes helps clarify which approach aligns with specific goals. Lean mass accretion, metabolic support, bone density preservation, or general longevity research. Most published trials weren't desig
This comparison does not assign a generated winner or score.
- Understanding how different MK-677 protocols produce varying outcomes helps clarify which approach aligns with specific goals. Lean mass accretion, metabolic support, bone density preservation, or general longevity research. Most published trials weren't designed to answer female-specific questions, but comparing protocol structure reveals where dosing, duration, and outcome measurement differ.
- Body Composition (Lean Mass Focus)
- 20–25mg daily
- 12–16 weeks
- Lean body mass via DEXA, nitrogen balance, basal metabolic rate
- Requires resistance training stimulus to maximize IGF-1 utilization; hunger management is critical for caloric control
- Best for women prioritizing muscle accretion and metabolic rate. Requires structured training and macros
- Bone Density Preservation
- 25mg daily
- 12+ months
- Bone mineral density (hip, lumbar spine), osteoblast markers (P1NP, osteocalcin)
- Most relevant for perimenopausal/postmenopausal women; requires baseline DEXA and monitoring
- Long-term protocol. Measurable bone density changes take 9–12 months to appear
- Metabolic/Longevity Research
- 10–15mg daily
- Continuous or pulsed (12 weeks on, 4–6 weeks off)
- Fasting glucose, HbA1c, lipid panel, inflammatory markers (hsCRP)
- Lower dose reduces insulin resistance risk; pulsing prevents receptor desensitization
- Conservative approach. Minimizes side effects while maintaining moderate IGF-1 elevation
- Sleep Quality and Recovery
- 10–20mg before bed
- Variable (4–12 weeks)
- Subjective sleep quality, REM/deep sleep percentage, next-day recovery markers
- Women report pronounced sleep depth improvements; may exacerbate vivid dreams in some individuals
- Common ancillary use. Often combined with other recovery protocols rather than standalone
- The comparison reveals that MK-677 for women isn't a monolithic protocol. The dose, duration, and outcome priorities should match the specific biological goal. Lean mass protocols require higher doses and structured training; bone density research requires year-long timelines; metabolic support benefits from lower, sustained dosing with periodic breaks.